Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, outlines her hopes from the St Gallen Breast Cancer Consensus (BCC) 2023. The practical difficulties of achieving new significant early results is noted with ER+ HER2- breast cancer, which is singled out as a disease that requires particularly long-term follow-up to produce significant results. Results may soon be available on the adjuvant role of ribociclib, with Dr Ciruelos expecting that data will be presented at this conference. Finally, individualised medicine improvements are also expected from BCC 2023. Improved diagnostic methods such as HER2DX are highlighted as key tools to de-escalate excessively expansive treatment plans, and promote more specific and relevant breast cancer treatment. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.